BTXA-51 is under clinical development by Edgewood Oncology and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to GlobalData, Phase II drugs for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) have a 49% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BTXA-51’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BTXA-51 overview

BTXA-51 is under development for the treatment of relapsed or refractory acute myeloid leukemia, high risk myelodysplastic syndrome, metastatic solid tumor, estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) metastatic breast cancer and B-cell non-Hodgkin lymphoma. It is administered by oral route. The drug candidate is a multi-kinase inhibitor that acts by targeting casein kinase I alpha (CKI-alpha) as well as super enhancer targets (CDK7/CDK9).

Edgewood Oncology overview

Edgewood Oncology offers healthcare services including cancer, hematology, oncology and medical care services. The company is headquartered in New Castle, Delaware, the US.

For a complete picture of BTXA-51’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.